SRR1416096
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.429
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.365
- ANGIOGENESIS+0.275
- MYOGENESIS+0.274
- INFLAMMATORY_RESPONSE+0.260
- KRAS_SIGNALING_UP+0.226
- BILE_ACID_METABOLISM+0.212
- COAGULATION+0.208
- ALLOGRAFT_REJECTION+0.203
- PANCREAS_BETA_CELLS+0.183
Top 10 suppressed
- MYC_TARGETS_V2-0.566
- DNA_REPAIR-0.558
- MYC_TARGETS_V1-0.547
- UNFOLDED_PROTEIN_RESPONSE-0.547
- OXIDATIVE_PHOSPHORYLATION-0.546
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.528
- PROTEIN_SECRETION-0.515
- MTORC1_SIGNALING-0.507
- UV_RESPONSE_UP-0.390
- PI3K_AKT_MTOR_SIGNALING-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1440246 | GTEX | — | 0.970 |
| 2 | SRR1394713 | GTEX | — | 0.966 |
| 3 | SRR1486863 | GTEX | — | 0.962 |
| 4 | SRR1316624 | GTEX | — | 0.959 |
| 5 | SRR1421093 | GTEX | — | 0.958 |
| 6 | SRR1343197 | GTEX | — | 0.955 |
| 7 | SRR1444479 | GTEX | — | 0.954 |
| 8 | SRR1348861 | GTEX | — | 0.953 |
| 9 | SRR1451964 | GTEX | — | 0.953 |
| 10 | SRR1339549 | GTEX | — | 0.952 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.429 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.365 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.275 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.274 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.260 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.226 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.212 | Inavolisib | — uncovered |
| COAGULATION | 0.208 | Binimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.203 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.183 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.145 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.139 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.092 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.051 | Inavolisib | — uncovered |
| COMPLEMENT | 0.021 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.005 | Inavolisib | — uncovered |